Published in BMJ on May 15, 1999
Role of antioxidant vitamins in prevention of cardiovascular diseases. Meta-analysis seems to exclude benefit of vitamin C supplementation. BMJ (1999) 0.85
Design of a randomized controlled trial of comprehensive rehabilitation in patients with myocardial infarction, stabilized acute coronary syndrome, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting: Akershus Comprehensive Cardiac Rehabilitation Trial (the CORE Study). Curr Control Trials Cardiovasc Med (2000) 0.80
Chronic Alcohol Consumption Leads to a Tissue Specific Expression of Uncoupling Protein-2. Int J Med Sci (2015) 0.75
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA (1995) 11.45
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med (1996) 10.09
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst (1993) 8.30
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet (1992) 7.22
Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA (1998) 7.09
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet (1996) 6.48
Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature (1992) 5.56
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39
Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med (1997) 5.35
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med (1995) 5.22
Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med (1979) 4.94
Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA (1996) 4.29
Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet (1997) 4.19
Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA (1997) 3.87
Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med (1991) 3.86
Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation (1995) 3.82
The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med (1984) 3.71
Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med (1996) 3.34
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 3.28
Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA (1995) 2.87
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61
The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med (1995) 2.32
Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation (1998) 2.31
Plasma renin activity and ischemic heart disease. N Engl J Med (1993) 1.71
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation (1994) 1.67
A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation (1996) 1.64
Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chronic Dis (1974) 1.60
Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation (1998) 1.51
Homocysteine theory of arteriosclerosis. Atherosclerosis (1976) 1.43
Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk (1998) 1.43
Homocysteine and coronary atherosclerosis. J Am Coll Cardiol (1996) 1.39
Relation of vitamin C levels to mortality in a geriatric hospital: a study of the effect of vitamin C administration. Age Ageing (1973) 1.27
Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation (1992) 1.15
Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA (1996) 1.10
Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation. JAMA (1996) 1.10
Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. Can J Cardiol (1997) 1.04
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol (1994) 1.03
Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. Eur Heart J (1998) 0.92
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol (1994) 0.87
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med (2001) 20.20
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care (1999) 9.16
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 8.54
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet (2000) 8.01
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Emerging epidemic of cardiovascular disease in developing countries. Circulation (1998) 6.41
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45
Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet (1996) 4.28
Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA (1993) 4.01
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet (1998) 3.79
Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet (2002) 3.77
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation (1990) 3.72
Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J (1996) 3.66
Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med (1999) 3.63
Epidemiology and causation of coronary heart disease and stroke in India. Heart (2008) 3.60
Health and peace: time for a new discipline. Lancet (2001) 3.52
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. CMAJ (1999) 3.18
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ (1996) 2.90
Prevalence of coronary artery disease in Asian Indians. Am J Cardiol (1992) 2.90
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost (2011) 2.87
Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ (1991) 2.81
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation (2007) 2.76
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet (2000) 2.74
Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation (1994) 2.61
The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med (1995) 2.32
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ (1989) 2.27
Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) (1985) 2.27
Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet (2000) 2.17
Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China study. Heart (2009) 2.16
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension (2001) 2.15
Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention. Circulation (1993) 2.15
Acute precipitants of congestive heart failure exacerbations. Arch Intern Med (2001) 2.11
Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol (2001) 2.05
Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet (1980) 2.00
Can medicine prevent war? Imaginative thinking shows that it might. BMJ (1999) 1.95
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol (1991) 1.94
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials (1997) 1.88
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J (2000) 1.88
Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation (1995) 1.85
Magnesium in acute myocardial infarction. BMJ (1995) 1.80
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76
Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. Int J Obes (Lond) (2005) 1.72
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J (2000) 1.72
Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol (1996) 1.64
Increased risk of acute myocardial infarction associated with beedi and cigarette smoking in Indians: final report on tobacco risks from a case-control study. Indian Heart J (2002) 1.62
Education and risk for acute myocardial infarction in 52 high, middle and low-income countries: INTERHEART case-control study. Heart (2009) 1.61
Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA (1993) 1.60
Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol (1985) 1.60
Increased winter mortality from acute myocardial infarction and stroke: the effect of age. J Am Coll Cardiol (1999) 1.59
Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol (2001) 1.58
Meeting of the International Working Group on Coronary Artery Disease in South Asians. 24 March 1996, Orlando, Florida, USA. Indian Heart J (1997) 1.58
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol (1996) 1.55
Dual-chamber versus ventricular pacing. Critical appraisal of current data. Circulation (1996) 1.55
The entry ECG in the early diagnosis and prognostic stratification of patients with suspected acute myocardial infarction. Eur Heart J (1984) 1.55
Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia (2010) 1.54
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2002) 1.51
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation (1998) 1.51
Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy. JAMA (2001) 1.50
Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol (1993) 1.49
Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation (1995) 1.49
The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol (2003) 1.49
Validity of the US Behavioral Risk Factor Surveillance System's health related quality of life survey tool in a group of older Canadians. Chronic Dis Can (2001) 1.47
Urate levels as a predictor of cardiac deaths: causal relation or mere association? Eur Heart J (2002) 1.40
Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. Eur Heart J (2002) 1.40
Strengths and limitations of meta-analysis: larger studies may be more reliable. Control Clin Trials (1997) 1.36
Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). Indian Heart J (2001) 1.33
Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail (1999) 1.32
Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA (1988) 1.29
Dysglycaemia and risk of cardiovascular disease. Lancet (1996) 1.29
Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation (1996) 1.27
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J (2006) 1.24
The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Can J Cardiol (1998) 1.22
Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J (2001) 1.22
Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. Am Heart J (1982) 1.21
A cardiologist's guide to waist management. Heart (2006) 1.20